Table 2:

Multivariate Analysis of Predictors for CRM Positivity

Variable	OR	95% CI	P
AGE(71 vs. 52)	1.04	0.98 – 1.12	0.21
Tumor.size (50 vs. 24)	1.06	0.99 – 1.14	0.091
Gender - Female:Male	0.97	0.89 – 1.07	0.558
Race - Black:White	1.1	0.94 – 1.29	0.231
Race - Other:White	1.06	0.87 – 1.29	0.586
Comorbidity - Charlson-DeyoScore 1:0	0.93	0.83 – 1.04	0.211
Comorbidity - Charlson-DeyoScore 2:0	0.93	0.76 – 1.14	0.474
Tumor Differentiation - I:II	1	0.84 – 1.18	0.969
Tumor Differentiation - III:II	1.54	1.35 – 1.75	<0.001
Tumor Differentiation - IV:II	1.99	1.49 – 2.66	<0.001
HISTOLOGY - Mucinous:Adenocarcinoma	2.07	1.77 – 2.42	<0.001
HISTOLOGY - Signet :Adenocarcinoma	1.76	1.19 – 2.61	0.005
Neoadjuvant Chemo - No:Yes	1.2	1 – 1.44	0.047
Neoadjuvant ChemoXRT - No:Yes	1.16	0.97 – 1.39	0.108
Type of Operation - APR:LAR	1.35	1.22 – 1.49	<0.001
Surgical Approach - MinimallyInvasive:Open	0.84	0.77 – 0.92	<0.001
TNM T Stage - T1:T3	0.83	0.7 – 0.98	0.029
TNM T Stage - T2:T3	0.7	0.6 – 0.81	<0.001
TNM T Stage - T4:T3	2.37	2.06 – 2.73	<0.001
TNM T Stage - T.Others:T3	1	0.9 – 1.11	0.971
TNM N Stage - N1:N0	1.11	0.94 – 1.32	0.198
TNM N Stage - N2:N0	1.15	0.76 – 1.74	0.511
TNM N Stage - Nx:N0	1.49	1.31 – 1.7	<0.001
Lymphovascular invasion - Yes:No	2.54	2.25 – 2.88	<0.001
Perineural invasion - Yes:No	1.42	1.26 – 1.6	<0.001
CEA - Elevated:Normal	0.89	0.42 – 1.88	0.755
CEA - Borderline:Normal	1.04	0.98 – 1.12	0.21